Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma
Regeneron has won US Food and Drug Administration (FDA) approval for Lynozyfic (linvoseltamab-gcpt), marking the entry of another BCMAxCD3 bispecific …
Post
-
-
Ligand’s LNHC concludes merger with CHRO
Ligand Pharmaceuticals’ wholly owned subsidiary LNHC has concluded its merger with Channel Therapeutics’ CHRO Merger Sub, resulting in the formation …
-
Navigating the AI regulatory maze: Why 91% of life sciences professionals feel lost
Only 9% of life sciences professionals understand U.S. and EU artificial intelligence (AI) regulations well.[1] Let that sink in. While your executive …
-
Podcast: The importance of Social Determinants of Health (SDoH)
As the focus on personalized, equitable healthcare continues to intensify, social determinants of health (SDoH) have attracted significant attention in …
-
FDA approves Dizal’s Zegfrovy to treat adults with NSCLC
Dizal has received US Food and Drug Administration (FDA) approval for Zegfrovy (sunvozertinib) to treat adults with locally advanced or …
-
Protecting patients’ data is vital for NHS single health record system
Experts are emphasising that safeguarding patient data from corporations and cyberattacks is vital for the NHS to create a single …
-
Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention
Gilead’s recently approved drug for HIV prevention, Yeztugo (lenacapavir), has the potential to transform the pre-exposure prophylaxis (PrEP) sector in …
-
Sanofi agrees to invest $25m in Adagene
Sanofi has agreed to invest up to $25m in Adagene, which will enable the latter to fund its research and …
-
Trump tax bill estimated to cut Medicaid spend by $1trn passes US Senate
US President Donald Trump’s One Big Beautiful Bill Act (H.R. 1) has narrowly passed after US Vice President JD Vance …
-
Vertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold
Vertex Pharmaceuticals has won approval in Europe for its next-generation cystic fibrosis therapy Alyftrek (deutivacaftor/tezacaftor/vanzacaftor), shoring up the company’s dominance …
-
Merck concludes SpringWorks acquisition for $3.4bn
Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving …
-
Cell and gene therapy: The vital role of logistics
Cell and gene therapies (CGT) offer hope to patients living with life-threatening conditions where limited treatment options may be available …
-
Uruguay progresses towards developing its first regulatory agency
Uruguay’s new left-wing coalition government took office in March 2025, under President Yamandu Orsi. Part of his new agenda has …
-
EC approves Jazz Pharmaceuticals’ Ziihera for biliary tract cancer
Jazz Pharmaceuticals has received conditional marketing authorisation from the European Commission (EC) for its new bispecific antibody, Ziihera (zanidatamab), for …
-
Oncternal sells assets for up to $68m and calls it quits
American oncology company Oncternal Therapeutics is to wind down operations after announcing the sale of its main drug programmes. Delaware-based Ho’ola …
